Are Dilated Fundus Examinations Needed for OCT-Guided Retreatment of Exudative Age-Related Macular Degeneration? A Prospective, Randomized, Pilot Study

por Solomon SD, Kyerematen V, Qutab M, Wenick AS, Wang J, Hawkins BS
Publicado 2021

Brolucizumab: evidence to date in the treatment of neovascular age-related macular degeneration

por Yannuzzi NA, Freund KB
Publicado 2019

Vision Recovery Velocity, Momentum and Acceleration: Advanced Vitreoretinal Analytics as Measure of Treatment Efficacy for Neovascular Age-Related Macular Degeneration

por Almeida DRP, Ruzicki J, Xu K, Chin EK
Publicado 2021

Long-Term Ranibizumab Treatment in Neovascular Age-Related Macular Degeneration: A Belgian Subanalysis from the Global Real-World LUMINOUSTM Study

por Leys AM, Ramboer E, Favreau M, Denhaerynck K, MacDonald K, Abraham I, Brié H
Publicado 2020

Quantitative Comparison of the Vascular Structure of Macular Neovascularizations Between Swept-Source and Spectral-Domain Optical Coherence Tomography Angiography

por Faatz H, Rothaus K, Ziegler M, Book M, Lommatzsch C, Spital G, Gutfleisch M, Pauleikhoff D, Lommatzsch A
Publicado 2020

Real-World Effectiveness, Treatment Pattern, and Safety of Ranibizumab in Korean Patients with Neovascular Age-Related Macular Degeneration: Subgroup Analyses from the LUMINOUS Stu...

por Sagong M, Woo SJ, Lee Y
Publicado 2021

Evaluation of contrast sensitivity and other visual function outcomes in neovascular age-related macular degeneration patients after treatment switch to aflibercept from ranibizuma...

por Nixon DR, Flinn NAP
Publicado 2017

Aflibercept treatment for neovascular AMD beyond the first year: consensus recommendations by a UK expert roundtable panel, 2017 update

por Patel PJ, Devonport H, Sivaprasad S, Ross AH, Walters G, Gale RP, Lotery AJ, Mahmood S, Talks JS, Napier J
Publicado 2017

Therapeutic Potential of the Ranibizumab Port Delivery System in the Treatment of AMD: Evidence to Date

por Chen ER, Kaiser PK
Publicado 2020

Five-year outcomes of intravitreal drug therapy for neovascular age-related macular degeneration in eyes with baseline vision 20/60 or better

por Khanani AM, Gahn GM, Koci MM, Dang JM, Brown SM, Hill LF
Publicado 2019

Efficacy and safety of ranibizumab monotherapy versus ranibizumab in combination with verteporfin photodynamic therapy in patients with polypoidal choroidal vasculopathy: 12-month...

por Takahashi K, Ohji M, Terasaki H, Honda S, Margaron P, Guerin T, Yuzawa M
Publicado 2018

Real-World Outcomes of Intravitreal Aflibercept for Neovascular Age-Related Macular Degeneration: A Large-Scale Postmarketing Surveillance in Korea

por Ryu G, Noh D, Moon G, Sagong M
Publicado 2021

Ten-Year Real-World Outcomes of Anti-Vascular Endothelial Growth Factor Therapy in Neovascular Age-Related Macular Degeneration

por Cheema MR, DaCosta J, Talks J
Publicado 2021

Neovascular age-related macular degeneration without drusen in the fellow eye: clinical spectrum and therapeutic outcome

por Chung WH, van Dijk EHC, Mohabati D, Dijkman G, Yzer S, de Jong EK, Fauser S, Schlingemann RO, Hoyng CB, Boon CJF
Publicado 2016

Neovascular age-related macular degeneration: intraocular inflammatory cytokines in the poor responder to ranibizumab treatment

por Pongsachareonnont P, Mak MYK, Hurst CP, Lam WC
Publicado 2018

Management of neovascular age-related macular degeneration: Taiwan expert consensus

por Ling Yeung, Yi-Ting Hsieh, Chang-Hao Yang, Lee-Jen Chen, Shih-Jen Chen, Cheng-Kuo Cheng, Shwu-Jiuan Sheu, Ching-Yao Tsai, Tsung-Tien Wu, Wei-Chi Wu, San-Ni Chen
Publicado 2021

Patient Preferences Associated with Anti-Vascular Endothelial Growth Factor Therapies for Neovascular Age-Related Macular Degeneration and Diabetic Macular Edema

por Bhagat D, Kirby B, Bhatt H, Jager R, George M, Sheth V
Publicado 2020

Short-Term Efficacy and Safety Outcomes of Brolucizumab in the Real-Life Clinical Practice

por Andrea Montesel, Claudio Bucolo, Ferenc B. Sallo, Chiara M. Eandi
Publicado 2021

The Impact of Non-Ophthalmic Factors on Intravitreal Injections During the COVID-19 Lockdown

por Ashrafzadeh S, Gundlach BS, Tsui I
Publicado 2021

Two-year outcome of treat-and-extend aflibercept after ranibizumab in age-related macular degeneration and polypoidal choroidal vasculopathy patients

por Azuma K, Asaoka R, Matsuda A, Lee J, Shimizu K, Inui H, Murata H, Ogawa A, Yamamoto Motoshi, Inoue T, Obata R
Publicado 2018